Global Sepsis Diagnostic Market Size, Share & Trends Analysis Report By Product (Instruments, Software, Blood Culture Media, Assays & Reagents, Others), By Technology (Flow Cytometry, Microbiology, Biomarkers, Molecular Diagnostics, Microfluidics, Others), By Diagnostic Method (Automated Diagnostics,Conventional Diagnostics), By Pathogen (Fungal Sepsis, Bacterial Sepsis, Other Pathogens), By End-user (Hospitals, Pathology & Reference Laboratories, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), And Segment Forecasts, 2024 – 2031
Report Overview
The Global Sepsis Diagnostics Market reached US$ 710.13 million in 2023 and is expected to reach US$ 1,435.24 million by 2031, growing at a CAGR of 9.5% during the forecast period 2024-2031.
Sepsis is a life-threatening illness that occurs when the body's immune system overreacts to an infection, causing organ malfunction. The body's response damages its tissues and organs, which can result in shock, multiple organ failure, and even death if not detected and treated swiftly.
Blood tests and other lab tests such as urine, liquid from the wound, mucus, and saliva from the respiratory tract are performed to diagnose the condition.
Market Scope
|
Metrics |
Details |
|
CAGR |
9.5% |
|
Market Size Available for Years |
2022-2031 |
|
Estimation Forecast Period |
2024-2031 |
|
Revenue Units |
Value (US$ Mn) |
|
Segments Covered |
Product, Technology, Diagnostic Method, Pathogen, End-User |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
|
Largest Region |
North America |
|
Fastest Growing Region |
Asia-Pacific |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
The growing burden of infectious diseases
If infectious infections are not detected and treated promptly, they can develop into serious conditions such as sepsis. As a result, there is a greater emphasis on early diagnosis of infections that could develop into sepsis. Diagnostic tests for sepsis assist healthcare providers in detecting the condition early, allowing for appropriate intervention and management. HAIs are hospital-acquired infections that can significantly contribute to sepsis cases.
As healthcare-associated infections continue to rise, there is a greater need for precise diagnostic tools to monitor patients and diagnose sepsis early in these settings.
In Europe, the burden of the six most frequent HAIs was calculated to be twice the burden of 32 other infectious diseases altogether, in terms of disability and premature mortality.
Additionally, according to research published by 2023 Balasubramanian et al., an estimated 136 million cases of healthcare-associated antibiotic-resistant infections occur worldwide every year. Thus, the increasing burden of infectious diseases is expected to drive the market growth.
High Cost of Diagnostic Tools
Automated diagnostic instruments and biomarker tests can be costly. High upfront expenses could result in a slower overall adoption rate among medical facilities. This directly translates into slower growth in the sepsis diagnostics market. Despite these limitations, hospitals will continue to use older, less expensive methods.
Segment Analysis
The global sepsis diagnostic market is segmented based on product, technology, diagnostic method, pathogen, end-user and region.
Blood Culture Media segment is expected to dominate the market growth
Blood culture media is expected to be the dominant segment in the sepsis diagnostics market. Blood culture media is a less expensive diagnostic technique than other approaches such as molecular diagnostics. Blood culture media is readily accessible and simple in most therapeutic settings.
While more rapid approaches are emerging, blood cultures remain the accepted standard for identifying the specific pathogens causing sepsis since they allow for the growth and identification of bacteria or fungi. Thus, the above factors are expected to hold the segment in the dominant position.
Geographical Analysis
North America is expected to hold a significant position in the sepsis diagnostic market share
North America is expected to dominate the sepsis diagnostic market owing to the increasing prevalence of sepsis and the technological advancements in sepsis diagnosis such as advanced diagnostic facilities and high adoption rates of medical technologies are expected to drive the market growth in the region. The medical diagnostic companies in the region are introducing several tests and the required sepsis diagnostic tools which could help in driving the market growth.
Foe instance, in August 2023, Medical diagnostic company Cytovale commercially introduced its new diagnostic tool, the IntelliSep sepsis test, in the US. The test was launched following 510(k) clearance from the US Food and Drug Administration in December 2022.
Additionally, on April 3, 2024, Prenosis, Inc. received the U.S. Food and Drug Administration (FDA) approval of the marketing authorization for the Sepsis ImmunoScoreTM using the De Novo pathway. The Sepsis ImmunoScoreTM is an artificial intelligence/machine learning software as a medical device (AI SaMD) to guide rapid diagnosis and prediction of sepsis. Thus, the above factors are expected to hold the region in the dominant position.
Market Segmentation
By Product
- Instruments
- Software
- Blood Culture Media
- Assays & Reagents
- Others
By Technology
- Flow Cytometry
- Microbiology
- Biomarkers
- Molecular Diagnostics
- Microfluidics
- Others
By Pathogen
- Automated Diagnostics
- Conventional Diagnostics
By Diagnostic Method
- Fungal Sepsis
- Bacterial Sepsis
- Gram-Positive Bacterial Sepsis
- Gram-Negative Bacterial Sepsis
- Other Pathogens
By End-User
- Hospitals
- Pathology & Reference Laboratories
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the market include Thermo Fisher Scientific Inc., Bruker Corporation, Merck Millipore, Siemens Healthineers, Becton, Dickinson, and Company, Hoffmann-LA Roche Ltd, T2 Biosystems, Inc., Response Biomedical Corp., BioMérieux SA, and Immunexpress Inc. among others.
Key Developments
- On April 18, 2023, Carle Illinois College of Medicine faculty member Rashid Bashir received marketing approval from the Food and Drug Administration for A new AI tool for sepsis diagnosis developed from research.
- On November 27, 2023, Asep Medical Holdings Inc. secured patent approval in the US for its AI-based sepsis diagnostic technology, SepsetER.
Why Purchase the Report?
- To visualize the global Sepsis Diagnostic market segmentation based on Product, Technology, Diagnostic Method, Pathogen and End-User and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of Sepsis Diagnostic market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global Sepsis Diagnostic market report would provide approximately 53 tables, 47 figures and 176 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
